{
    "Trade/Device Name(s)": [
        "QMS\u00ae Quinidine",
        "EPY QMS\u00ae Quinidine"
    ],
    "Submitter Information": "Seradyn, Inc.",
    "510(k) Number": "K052826",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LBZ"
    ],
    "Summary Letter Date": "December 23, 2005",
    "Summary Letter Received Date": "October 5, 2005",
    "Submission Date": "October 4, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.3320"
    ],
    "Regulation Name(s)": [
        "Digoxin test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "chemistry"
    ],
    "Analyte(s)": [
        "Quinidine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Hitachi 717"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous particle-enhanced turbidimetric immunoassay",
        "Particle agglutination"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for QMS\u00ae Quinidine homogeneous particle-enhanced turbidimetric immunoassay for quantitative measurement of quinidine in human serum or plasma.",
    "Indications for Use Summary": "For quantitative determination of quinidine in human serum or plasma on automated clinical chemistry analyzers to aid diagnosis and treatment of quinidine overdose and monitor therapy.",
    "fda_folder": "Toxicology"
}